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Adenosine plays important role not only intra-
cellulary, but also as extracellular signal compound.
In the central neural system, adenosine modulates
sleep, locomotion, nociception, drug addiction and
other vitally important processes. Adenosine medi-
ates its actions through specific G protein-coupled
receptors, which are classified into four subtypes:
A1, A2A, A2B and A3 receptors (1). A1 and A2A recep-
tors bind adenosine with high affinity (kd 0.1 ñ 1.0
µM), whereas A2B and A3 receptors have lower affin-
ity for adenosine (kd 10 µM) (2). Adenosine A2A
receptors are localized in the central nervous sys-
tem, specially in striatum, where they modulate glu-
tamatergic neurotransmission via the GABAergic
enkephalinergic neurons (3). At the presynaptic
side, they are localized in active zone, forming het-
eromeric complexes mostly with adenosine A1, but
also with glutamatergic mGlu5 and dopaminergic D2
receptors. At the postsynaptic side they are localized
at the perisynaptic ring adjacent to the postsynaptic
density, forming heteromeric complexes with gluta-
matergic mGlu5 and dopaminergic D2 receptors. As
Gs, Golf proteins-coupled receptors, adenosine A2A
receptors transmit signal intracellulary, through
adenyl cyclase, protein kinase A cascade (4). A2A
and D2 receptors regulate the function of the
GABAergic enkephalinergic neurons by antagonis-
tic interactions (5, 6). Consequently, by blocking
adenosine A2A receptors, dopaminergic transmission
can be increased. This effect can be used in the new,
alternative therapies of some neurodegenerative dis-
orders, specially Parkinsonís disease (7). To date,
there is no drug with adenosine A2A receptor antag-
onistic properties in Parkinsonís disease available at
the European market, but some compounds are
being evaluated in clinical trials and one (Istra-
defylline) may reach the US market this year (8).
Green Fluorescent Protein (GFP) (9) and its
variants have become one of the most widely used
tools to study cellular distribution and trafficking of
proteins of interest. Genetic engineering of fluores-
cent proteins leads to different spectral properties,
increased brightness and folding efficiences, as
compared with the wild types (10). Attachment of
such proteins to the G protein-coupled receptors has
become widely applied method to study receptors in
living cells (11). Moreover, interactions between
receptors and other elements can be investigated in
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detail. For example, interaction with ligands with
agonistic/antagonistic properties (12), as well as
with G proteins can be visualized, as well as inter-
action with β-arrestines (13). Another area of inter-
ests, which has been widely investigated in recent
years is cross-talk between receptors of the same
type (homodimerization) or different types (het-
erodimerization) (14). The best established ways to
measure this type of protein-protein interactions are
resonance energy transfer and protein complemen-
tation assays. In both approaches both partners
require the attachment of the reporter proteins. In
resonance energy transfer assays one reporter is
donor fluorophore or bioluminescent protein and
the other reporter is longer wavelength acceptor flu-
orophore. The efficiency of non-radiative transfer
between donor and acceptor protein is determinated
by the distance between them (15). In protein com-
plementation assays the reporters are halves of a
protein, which can only function when the two frag-
ments are brought together and fold around each
other.
In the area of instrumentation, a great variety
of tools is presently offered. Steady-state fluores-
cence spectroscopy can be applied to get fluores-
cence emission spectra from cells population in
Figure 1. Flow cytometric profile of non-transfected HEK293 cells.
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solution. Flow cytometry offers fast and exact
measurements of each cell. Such parameters like
number, shape, viability, mobility, together with
fluorescent properties can be measured.
Fluorescent resonance energy transfer can be also
measured by flow cytometry (16). In order to visu-
alize fluorescent proteins fusion constructs distri-
bution and trafficking in living cells fluorescent
microscopy has to be applied. Confocal
microscopy offers better resolution, comparing
with white-field epifluorescence microscopy and a
possibility to measure energy transfer by acceptor
photobleaching. Fluorescence lifetime imaging
microscopy can provide quantitative information,
since fluorescence lifetime measurements are inde-
pendent of any change of fluorophore concentra-
tion or excitation intensity.
EXPRIMENTAL
Plasmids
The pcDNA 3.1 plasmid, encoding human
adenosine A2A receptor (UMR cDNA Resource
Center, Rolla, MO) was PCR-amplified using an
universal primer for pcDNA 3.1 and a reverse
primer without stop codon and carrying EcoRI
Figure 2. Flow cytometric profile of HEK293 cells transfected with EYFP-N1 plasmid.
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restriction site. The entire coding sequence was
inserted into pEYFP-N1 plasmid (Clontech, Palo
Alto, CA). 
Cell cultures and transfection 
Human embronic kidney 293 (HEK293) cells
were cultured at 37OC and 5% CO2 in DMEM medi-
um (Sigma), supplemented with 10% heat-inactivat-
ed FBS (Sigma) and 1% L-glutamine (Sigma). Cells
were transiently transfected using FuGene HD
reagent (Roche) for radioligand binding assays or
using Lipofectamine (Invitrogen) for epifluores-
cence microscopy, accoring to the manufacturers
instructions. 48 h after transfection cells were har-
vested for following experiments.
Epifluorescence microscopy
Cells were grown on poly(D-lysine)-treated
coverslips (number 0) and transiently transfected
with 2 µg of plasmid. Coverslips were placed into a
microscope chamber containing physiological
HEPES-buffered saline solution (130 mM NaCl, 5
mM KCl, 1 mM CaCl2, 1 mM MgCl2, 20 mM
HEPES, and 10 mMD-glucose, pH 7.4). Cells were
then imaged using an inverted Nikon TE2000-E
microscope (Nikon Instruments, Melville, NY)
Figure 3. Flow cytometric profile of HEK293 cells transfected with adenosine A2A receptor EYFP fusion construct.
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equipped with a 40 (numerical aperture 1.3) oilim-
mersion Fluor lens and a cooled digital photometrics
CoolSnap-HQ charge-coupled device camera
(Roper Scientific, Trenton, NJ). Epifluorescence
excitation light was generated by an ultra-highpoint
intensity 75 W xenon arc Optosource lamp (Cairn
Research, Faversham, Kent, UK) coupled to a com-
puter-controlled Optoscan monochromator (Cairn
Research). Monochromator was set at 495/9 nm.
Radioligand binding assay 
Radioligand binding assay was performed as
described in (17). Briefly, the transfected HEK 293
cells were washed with phosphonate-buffered saline
(PBS), scraped from dish in PBS and centrifuged at
1000 rpm for 5 min. Pellets were resuspended in 50
mM Tris-HCl, pH 7.4, containing 10 mM MgCl2,
using an Ultra Turrax homogenizer. This homo-
genate was recentrifuged at 48000 ◊ g for 10 min at
4OC. The resulting pellet was resuspended in buffer
containing 2 IU/mL of adenosine deaminase (Type
III, Boehringer Mannheim, Indianapolis, IN) to 20
mg/mL of original tissue weight and incubated at
37OC, in order to remove endogenous adenosine.
This membrane homogenate was recentrifuged and
the final pellet was used for the assay. The saturation
studies were carried out in triplicate, in tubes con-
taining 100-200 µg of protein per mL in incubation
buffer. Tubes were incubated with 10 different con-
centrations of [3H]CGS 21680 ranging from 0.5 to
50 nM. Nonspecific binding was defined in the pres-
ence of 20 µM 2-CADO. Binding reactions were
terminated by filtration through Whatman GF/B fil-
ters. Filters were washed twice with ice-cold buffer
and placed in scintillation vials and bound radioac-
tivity was determined by liquid scintillation count-
ing (Beckman LS 650). Estimation of the radioli-
gand binding parameters was carried out using the
GraphPad Prism 2.0 program (GraphPad Software,
San Diego CA).
Flow cytometry
Cells were transiently transfected using a calci-
um phosphonate precipitation procedure (18). 48 h
after transfection cells were harvested by tryp-
synization and resuspended in phosphonate buffer
saline with 1% bovine serum albumin. Data were
collected with FACSCalibur flow cytometer (BD
Biosciences, San Jose, CA), equipped with the
argon ion laser (wavelength of 488 nm) and a 635
nm Spectrum laser. Signals were detected with
530/30 nm bandpass filter (into FL1), 585/42 nm
bandpass filter (into FL2) and 670LP nm bandpass
filter (into FL3).
RESULTS
The aim of this study was to develop adenosine
A2A receptor fusion protein, which can be used in
various fluorescent-based assays. pEYFP-N1 plas-
mid, bearing enhanced yellow fluorescent protein
variant was employed and adenosine A2A receptor
was cloned into it. Obtained construct was sub-
cloned in Escherichia coli DH5a bacteria. In order to
get receptors expression in their functional form,
human HEK 293 cells were transiently transfected
with obtained construct by different methods, like
calcium phosphonate precipitation, FuGene HD or
Lipofectamine reagent. HEK 293 are cells of choice
in these type of experiments, because they offer high
fidelity of exogenous receptors expression, rapid
cell division and low patch-clamping (19). Flow
cytometric profile of non-transfected HEK 293 cells
(Figure 1) shows homogeneous population of non-
fluorescent cells. For cells transfected with pEYFP
plasmid (Figure 2), fluorescence is observed in all
detection channels, but the highest one is observed
in FL1 channel, what agrees with fluorescence emis-
sion maximum for yellow fluorescent protein. For
cells transfected with pEYFP plasmid, with adeno-
Figure 4. Fluorescence microscopy images of HEK293 cells trans-
fected with adenosine A2A receptor-EYFP fusion construct (left)
and EYFP plasmid alone (right). Figure 5. Saturation binding [3H] CGS 21680 to human adenosine
A2A receptors fused with EYFP fluorescent proteins, expressed in
HEK293 cells.
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sine A2A receptor encoding gene (Figure 3), the
highest fluorescence is observed, comparing with
cells transfected with pEYFP plasmid without the
insert. Epifluorescence imaging reveals membrane
localization of adenosine A2A receptors-EYFP
fusion proteins (Figure 4, left), comparing with dif-
fuse expression of enhanced yellow fluorescent pro-
teins alone (Figure 4, right), although, significant
fluorescence of fusion construct is observed in the
cells organelles.
In order to investigate the effect of the pres-
ence of fluorescent tag on receptors function, satura-
tion binding of specific adenosine A2A receptors
agonist [3H]CGS 21680 was performed (Figure 5).
The C-terminal tag did not influence the binding
parameters. The obtained kd values (14.9 nM) are
close to the values shown for these receptors in the
rat brain (17). 
DISCUSSION
The C-terminally tagged adenosine A2A rece-
ptors were expressed in HEK 293 cells, as judged
both by flow cytometry and by epifluorescence
microscopy imaging techniques. Most of the
expressed constructs were localized in the plasma
membrane, although significant fraction of expres-
sed constructs were localized in endoplasmic reticu-
lum and Golgi apparatus. This may indicate mis-
folding of some of the receptors constructs or that
portion of the receptor proteins is still on the way to
the final destination in the cell membrane. Satu-
ration binding experiments show that the fraction of
receptors construct present in the plasma membrane
is fully functional and able to bind specific ligands.
Continuing efforts to investigate obtained constructs
expression, advanced microscopic techniques like
confocal microscopy and fluorescence lifetime
imaging are planned to be used. 
The EYFP, like most of fluorescent proteins
available at the market have natural tendency to self
associate (20). This can be blocked with the A206K
point mutation in the amino acids sequence. The
monomeric fluorescent proteins, like for example
mCitrine (21) can replace the EYFP as fusion part-
ners and it may improve folding of fusion proteins
constructs.
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